AFFILIATIONS
1 Department of Molecular Medicine, Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic Graduate School of Biomedical Sciences, Rochester, Minnesota, United States, T Cell Engineering Laboratory, Mayo Clinic, Rochester, Minnesota, United States
2 Division of Hematology, Mayo Clinic, Rochester, Minnesota, United States, T Cell Engineering Laboratory, Mayo Clinic, Rochester, Minnesota, United States
3 Division of Hematology, Mayo Clinic, Rochester, Minnesota, United States, T Cell Engineering Laboratory, Mayo Clinic, Rochester, Minnesota, United States
4 Department of Immunology, Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic Graduate School of Biomedical Sciences, Rochester, Minnesota, United States, T Cell Engineering Laboratory, Mayo Clinic, Rochester, Minnesota, United States
5 Division of Hematology, Mayo Clinic, Rochester, Minnesota, United States, T Cell Engineering Laboratory, Mayo Clinic, Rochester, Minnesota, United States
6 Division of Hematology, Mayo Clinic, Rochester, Minnesota, United States, T Cell Engineering Laboratory, Mayo Clinic, Rochester, Minnesota, United States
7 Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic Graduate School of Biomedical Sciences, Rochester, Minnesota, United States, T Cell Engineering Laboratory, Mayo Clinic, Rochester, Minnesota, United States
8 Division of Hematology, Mayo Clinic, Rochester, Minnesota, United States, T Cell Engineering Laboratory, Mayo Clinic, Rochester, Minnesota, United States
9 Division of Hematology, Mayo Clinic, Rochester, Minnesota, United States, T Cell Engineering Laboratory, Mayo Clinic, Rochester, Minnesota, United States
10 Department of Immunology, Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic Graduate School of Biomedical Sciences, Rochester, Minnesota, United States, T Cell Engineering Laboratory, Mayo Clinic, Rochester, Minnesota, United States
11 Division of Hematology, Mayo Clinic, Rochester, Minnesota, United States, T Cell Engineering Laboratory, Mayo Clinic, Rochester, Minnesota, United States
12 Department of Immunology, Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic Graduate School of Biomedical Sciences, Rochester, Minnesota, United States, T Cell Engineering Laboratory, Mayo Clinic, Rochester, Minnesota, United States
13 Division of Hematology, Mayo Clinic, Rochester, Minnesota, United States, T Cell Engineering Laboratory, Mayo Clinic, Rochester, Minnesota, United States
14 Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic Graduate School of Biomedical Sciences, Rochester, Minnesota, United States, T Cell Engineering Laboratory, Mayo Clinic, Rochester, Minnesota, United States
15 Division of Hematology, Mayo Clinic, Rochester, Minnesota, United States, T Cell Engineering Laboratory, Mayo Clinic, Rochester, Minnesota, United States
16 Division of Hematology, Mayo Clinic, Rochester, Minnesota, United States, T Cell Engineering Laboratory, Mayo Clinic, Rochester, Minnesota, United States
17 Division of Hematology, Mayo Clinic, Rochester, Minnesota, United States, T Cell Engineering Laboratory, Mayo Clinic, Rochester, Minnesota, United States
18 Department of Immunology, Mayo Clinic, Rochester, Minnesota, United States, Department of Molecular Medicine, Mayo Clinic, Rochester, Minnesota, United States, Division of Hematology, Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic Graduate School of Biomedical Sciences, Rochester, Minnesota, United States, T Cell Engineering Laboratory, Mayo Clinic, Rochester, Minnesota, United States
ABSTRACT
Chimeric antigen receptor (CAR) T and CAR-NK therapies have transformed the treatment of hematologic malignancies, but relapse remains common due in part to chronic activation–induced effector cell dysfunction. SHIP-1, a negative regulator of PI3K signaling induced by cell activation, may contribute to this dysfunction. We hypothesized that SHIP-1 modulation reduces activation-induced dysfunction, prolongs cytotoxicity, and improves tumor control.
A short hairpin loop construct targeting SHIP-1 was delivered via lentiviral transduction and achieved high knockdown (KD) efficiency in NK cells (Avg. 35.8%, 21.6-42.4% n=5), and in T cells (Avg. 44.5%, 36.7-63.3% n=5). SHIP-1KD NK cells exhibited significantly enhanced killing of CD19+ JEKO-1 lymphoma cells compared to scramble (scRNA) controls. Importantly, this effect was most pronounced at later timepoints, with maximal difference in killing ability at 96-hours post co-culture (87.56% vs -34.82%, p<0.0001). To better model the tumor microenvironment, we cultured JEKO-1 cells with SHIP-1KD NK cells or controls at a variety of acidic pH levels. SHIP-1KD NK, but not scRNA NK cells, maintained effective killing at all tested pH (7.3: p<0.0001, 7.0: p<0.0001, 6.8: p<0.0001, 6.6: p=0.003).
Next, we tested the impact of SHIP-1KD on CAR engineered lymphocytes, using CD19-CAR (CAR19) as a model. SHIP-1KD CAR-NK19 and SHIP-1KD CART19 cells killed JEKO-1 cells more efficiently compared to scRNA CAR controls, respectively (83.72% vs 9%, p<0.0001; 66.1% vs 39.3%, p<0.0001). We then utilized an in vitro model for repeated CART19 cell stimulation to induce dysfunction through co-cultures with JEKO-1 cells every 2 days for a total of 8 days. SHIP-1KD CART19 outperform scRNA CART cells in measures of cytotoxicity (62.66% vs 42.1%, p=0.0023) and antigen specific proliferation (p<0.0001) on day 11 post repeated stimulation. In addition, SHIP-1KD CART19 exhibited significant reduction in expression of individual inhibitory receptors (CLTA-4 (21.2% vs 57.3%); PD-1 (15.6% vs 58.25%); TIM-3 (62.1% vs 87.75% ; LAG-3 (44.15% vs 75.9%), as well as reduced number of multiple (=4) inhibitory receptors per cell (11.35% vs 32.2%). Finally, SHIP-1KD CART19 sustained the ability to produce pro-inflammatory cytokines post-exhaustion compared to controls (IL-2: 9345.59 vs 3441.97 pg/ml, p=0.0003; GM-CSF: 4549.43 vs. 851.14 pg/ml, p=0.0352).
Transcriptomic interrogation of SHIP-1KD CART19 revealed enhancement in several genes related to cytotoxicity, persistence, and survival. Cytolytic molecules such as granzyme B (p<0.0001, logFC=6.13), granzyme A (p<0.0001, logFC=3.16), PRF1 (p<0.0001, logFC=1.4), and NKG7 (p<0.0001, logFC=1.95) were enriched in SHIP-1KD CART19. Pathway analysis revealed enrichment of genes involved in MTORC1 (normalized enrichment of 2.83, 124 genes) and IL2 STAT5 (normalized enrichment of 2.20, 72 genes) signaling.
Similarly, SHIP-1KD NK cells exhibited enhanced cytotoxicity against JEKO-1 cells upon repeated stimulation (80.93% vs 29.52%, p<0.0001). Upon activation with tumor cells, both SHIP-1KD NK and SHIP-1KD CAR-NK19 produced significantly higher levels of pro-inflammatory cytokines, such as myeloid and T-cell recruiting and activating factors (GM-CSF: 196.5 vs 92.55 pg/ml, p=0.0002; MIP1A: 719.47 vs. 383.95 pg/ml, p<0.0001; CXCL9: 381.91 vs. 128.32 pg/ml, p<0.0001), and significantly reduced pro-tumor angiogenic factors (PGDF-aa: 20.25 vs 155.4 pg/ml, p=0.0091) and (VEGF-A: 67.48 vs 1011.3 pg/ml, p<0.0001).
We then tested the efficacy of SHIP-1KD CART19 and SHIP-1KD CAR-NK19 in vivo. NSG mice were injected with 1x106 luciferase-positive JEKO-1 cells. After engraftment, mice were randomized to low dose SHIP-1KD CART19 or scRNA CART19 (0.5x106 cells i.v.). SHIP-1KD CART19 led to a significantly improved antitumor activity, as assessed by a decrease in BLI (7.18x109 vs 1.02x1011, p<0.0001) and improved survival (p<0.0001). For SHIP-1KD CAR-NK testing, JEKO-1 xenografts were randomized to treatment with a total dose of 12x106 of SHIP-1KD CAR-NK19 or scRNA CAR-NK19 cells. SHIP-1KD CAR-NK19 cells led to a significant reduction in tumor BLI compared to control (p<0.0001).
In summary, our results demonstrate that SHIP-1 modulation is an effective strategy for improving anti-tumor effector functions in both T and NK cells. SHIP-1 KD allows for persistent effector functionality in chronic stimulation, potentially abrogating the effects of activation induced hypo-functionality.